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Pefloxacin mesylate dihydrate (PFM) is a fluorinated quinolone structurally related
to nalidixic acid. Chemically, PFM, is 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-pepe-
razinyl)-4-oxo-3-quinolinecarboxylic acid, methane sulfonate dihydrate (Fig. 1). It is an
antibacterial drug, which is highly effective against both Gram-negative and Gram-posi-
tive pathogens that are resistant to other antibacterials (1). The therapeutic importance
of PFM has necessitated the development of analytical methods for its determination in
dosage forms in compliance with good manufacturing standards. The drug is official in
British and European Pharmacopoeias which describe a potentiometric non-aqueous ti-
tration procedure for its assay (2, 3). The drug has been determined in pharmaceutical
formulations by a variety of analytical techniques such as UV-spectrophotometry (4, 5),
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A spectrophotometric method is described for assay of
pefloxacin mesylate (PFM) in bulk drug and in tablets.
The method is based on back extraction of the bromo-
phenol blue dye at pH 5.2 from the dye-drug ion pair
followed by measurement of the dye absorbance at 590
nm. The working conditions of the method were investi-
gated and optimized. Beer’s law plot showed a good cor-
relation in the concentration range of 0.15–1.25 mg mL–1.
Sensitivity indices such as molar absorptivity, limits of
detection and quantification are reported. Intra-day and
inter-day precision, and accuracy of the methods were
established according to the ICH guidelines, and the er
values were in the range of –1.7 to 1.8% with RSD values
ranging from 1.0 to 1.1%. The method was successfully
applied to the assay of PFM in tablet preparations with
recoveries varying from 97.5 to 101.9%, with standard de-
viation in the range of 0.6 to 1.9. The results were statisti-
cally compared with those of the reference method by
applying Student’s t-test and F-test. Accuracy evaluated
by means of the spike recovery method, range from 97.0
to 106.0%, with precision better than 3%.
Keywords: pefloxacin mesylate, assay, spectrophotometry,
bromophenol blue, pharmaceuticals
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spectrofluorimetry (6, 7), capillary electrophoresis (8), polarography (9) and high perfor-
mance liquid chromatography (10–14). A few visible spectrophotometric methods based
on acid-base (15), redox (7, 16–18), oxidative coupling (19), complex formation (20–24)
reactions have been earlier reported for the determination of PFM in dosage forms. The
reported methods have their respective advantages and disadvantages as indicated in
Table 1. Therefore, it was considered desirable to develop an additional assay method
suitable for rapid and reliable quality control of PFM formulations. In this study, the vis-
ible spectrophotometric approach was followed to develop a sensitive and selective pro-
cedure for the determination of PFM in commercial dosage forms.
EXPERIMENTAL
Apparatus
A Systronics model 106 digital spectrophotometer (Systronics India Ltd., India) with
1-cm matched quartz cells was used for all absorbance measurements.
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PFM-BPB complex (pH 3.0)
pH 5.2
Fig. 1. Tentative reaction scheme.
Reagents and materials
All chemicals used were of analytical reagent grade and all solutions were freshly
prepared in doubly distilled water. Spectrophotometric grade chloroform (Ranbaxy Fine
Chem, Ltd., India) was used for extraction.
Phthalate buffers (pH 3.0 and 5.2) were prepared by adjusting the pH of 0.1 mol L–1
potassium hydrogen phthalate (S. d. Fine Chem., India) with 0.1 mol L–1 hydrochloric
acid and 0.1 mol L–1 sodium hydroxide, respectively. A 0.1% solution of Bromophenol
blue (BPB) was prepared by dissolving the dye (Rankem, India, 95% dye content) in wa-
ter and filtering it to remove the insoluble residue.
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Vanadium(V) 766 10–40 Heating, 30 min, narrow
linear range, less sensitive
7
NaOH-phenol red 560 5–40 5.91 ´ 103 Critical dependence on
NaOH concentration
15
Folin-Ciocalteau reagent 670 10–45 2.8 ´ 103 Less selective, less sensitive
and narrow linear and
dynamic range
16
Iron(III) chloride 440 10–100 Less sensitive, shorter
wavelength
17

















Iron(III) nitrate/NaNO3 404 4.7–13.7 4.8 ´ 103 Shorter wavelength, narrow















Methyl orange 424 4–40 23
Bromocresol green 420 2–16 24
Bromophenol blue 590 0.15–1.25 2.40 ´ 105 Highly sensitive this
paper
MBTH – 3-methylbenzothiazoline-2-one hydrazone
DDQ – 2,3-dichloro-5,6-dicyano-p-benzoquinone
Pharmaceutical grade PFM was kindly gifted by Cipla India Ltd. (India). A stock
standard solution containing 1 mg mL–1 of PFM was prepared in water. Working stan-
dard solution equivalent to 5 mg mL–1 PFM was obtained by appropriate dilution of stock
solution.
The following dosage forms containing PFM were purchased from local commercial
sources: A – Peflex tablets (Wockhardt, India), 200 and 400 mg of PFM, B – Pefbid tablets
(Megacarem, India), 400 mg of PFM, C – Qucin tablets (Aristo Pharma Pvt. Ltd. India),
400 mg of PFM, and D – Peflobid injections equivalent to 2 mg mL–1 PFM (Cadila, In-
dia).
Analytical procedures
Calibration graph. – Twenty mL of PFM solution (5 mg mL–1) was pipetted into a
125-mL separating funnel, 4 mL of BPB (0.1%) and 20 mL phthalate buffer (pH 3.0) were
added and the total volume of aqueous phase was made up to 60 mL with water. Chlo-
roform (20 mL) was added and the contents were shaken for 1 min; the separated chlo-
roform layer was dried over anhydrous sodium sulphate and collected in a 25-mL cali-
brated flask. Different aliquots of the chloroform extract (drug-dye ion-pair equivalent
to 5 g mL–1 PFM) were accurately measured and transferred into a series of 125-mL
separating funnels and then, 5 mL of phthalate buffer (pH 5.2) added to each separating
funnel. The contents were shaken for 1 min and the absorbance of the separated aqueous
layer was measured at 590 nm against a reagent blank.
Detection and quantification limits. – The limit of detection (LOD) and limit of quanti-
fication (LOQ) were calculated according to the current ICH guidelines as the ratio of 3.3
and 10 standard deviations of the blank (n = 7), respectively, and the slope of the calibra-
tion line (25).
Procedure for dosage forms. – Twenty PFM tablets were chosen randomly from a total
number of 50. They were weighed accurately and ground into a fine powder. An amount of
powder equivalent to approximately 20 mg of PFM was accurately weighed into a 100-mL
calibrated flask, 50 mL of water was added and the content was shaken for 15–20 min.
Then, the volume was finally diluted to the mark with water, mixed well and filtered us-
ing a Whatman No. 42 filter paper. The first 10-mL portion of the filtrate was discarded,
and the tablet extract (200 µg mL–1 in PFM) was diluted with water to get 5 mg mL–1
PFM solution for assay. The contents of 20 ampoules containing injectables were pooled
and an aliquot equivalent to 20 mg of PFM was accurately measured and diluted to 100 mL
in a calibrated flask and mixed. After necessary dilution, the solution was assayed as
stated before.
Selectivity studies. – As synthetic mixture consisting of PFM, talc, starch, lactose, gum
acacia, sodium alginate, magnesium stearate, calcium gluconate, and calcium dihydro-
genorthophosphate in the ratio 1:1.5:2:1.5:0.5:2.5:3.0:1:0.5 was prepared by thorough mix-
ing of the constituents. An amount of the mixture equivalent to 20 mg of PFM was accu-
rately weighed into a 100-mL calibrated flask and the drug was extracted with water
and the steps described under the assay of dosage forms were followed to determine the
percent recovery of PFM. The results are presented in Table V.
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RESULTS AND DISCUSSION
The described method is based on the formation of a chloroform soluble ion-pair
between PFM and BPB followed by measurement of the back-extracted dye.
Optimization of experimental conditions
While studying the effect of pH, the drug-dye ion-pair formation was found to be
critically dependent on the pH of the aqueous phase and at pH values higher than 4.8 no
ion-pair was formed, i.e., the ion-pair was found to break into its constituent ions. This
observation was exploited to develop a highly sensitive method for PFM. In this me-
thod, the ion-pair formed at pH 3.0 and extracted into chloroform was back-extracted
with a buffer of pH 5.2 and the absorbance of the aqueous buffer phase was measured at
590 nm (Fig. 2).
Several organic solvents such as benzene, toluene, cyclohexane, carbon tetrachlo-
ride, methylene chloride and i-amylalcohol in addition to chloroform were examined for
their ability to extract the drug-dye ion-pair. The latter was found to be the most suitable
solvent in terms of extraction efficiency.
Optimum conditions for quantitative extraction of the dye from the drug-dye ion-
-pair were also investigated. The absorbance was maximal and constant over the pH
range 4.8–5.6; hence, pH 5.2 was selected. The extraction was also affected by the nature
of the buffer employed. Of the several (pH 5.2) buffers tested, such as phthalate-NaOH,
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Fig. 2. Absorption spectra of back extracted dye:
a) 1.13 mg mL–1 PFM, b) 0.63 mg mL–1 of PFM, c) blank.
acetate-acetic acid, succinic acid-borax, the first buffer was found to provide efficient ex-
traction. A single extraction with 5 mL of buffer was found to be adequate for the con-
centration range investigated. Shaking times ranging from 0.5 to 3 min produced no
change in absorbance; so a one min shaking time was selected. The absorbance of the
aqueous phase was found to be constant over several weeks.
Method validation
Under the experimental conditions described, Beer’s law was obeyed over 0.15–1.25
mg mL–1 PFM. The calculated molar absorptivity was 2.40 × 105 L mol–1 cm–1. The LOD
and LOQ values were calculated to be 0.03 and 0.10 mg mL–1, respectively. The equation
relating the absorbance to concentration was:
A = –0.025 + 0.826 g (R = 0.9986, n = 7)
where A is the absorbance, g is concentration of PFM in mg mL–1 and R is the coefficient
of correlation.
In order to determine the intra-day accuracy and precision of the methods, soluti-
ons containing three different concentrations (within the working limits) of the drug
were prepared and analyzed in seven replicates. The results obtained from this investi-
gation are summarized in Table II. The relative standard deviation ( 1.1%) indicates the
high intra-day precision of the methods. The accuracy defined in terms of percent devia-
tion of the calculated concentrations ( 2%) can be considered satisfactory. The inter-day
precision was evaluated by performing replicate analyses on pure drug solution at three
concentration levels over a period of five days by preparing all solutions afresh each
day. The inter-day RSD values ranged from 1.5–3.5%, reflecting the usefulness of the
method in routine use (Table II).
The results of the selectivity studies as shown in Table V confirm that the proposed
method is accurate and precise even in the presence of various excipients (recovery 97.6
± 0.8%).
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0.200 98.0 1.0 0.196 ± 0.002 1.5
0.600 98.3 1.1 0.590 ± 0.006 2.8
1.000 101.8 1.0 1.018 ± 0.009 3.5
a Average value of seven determinations.
CL – Confidence limits at the 95% confidence level for six degrees of freedom.
Application to dosage forms
In order to demonstrate the usefulness of the proposed method, PFM was deter-
mined in authentic samples (pharmaceuticals). The results agreed with the nominal con-
tents (recovery 97.5–101.9%) (Table III). The results were also compared statistically by
Student’s t-test for accuracy and the variance ratio F-test for precision with the official
potentiometric method (3) at the 95% confidence level with four degrees of freedom. The
results showed that the proposed method and the official method are comparable in
terms of accuracy and precision.
The reliability and accuracy of the methods were further confirmed by performing
recovery studies. To a fixed and known quantity of the pre-analyzed tablet powder or
injectable product, pure PFM (standard) was added at three different concentration lev-
els, and the total was found by the proposed methods. The experiment was repeated
three times at each level. The percent recoveries of the pure drug added (97.0–106.0%),
(Table IV), additionaly reveal the fair selectivity of the method.
The proposed method is simple, rapid, accurate and precise. From Table I, it is clear
that the proposed spectrophotometric method is highly selective compared to most ex-
isting methods (7, 15–25). The most striking feature of the method is its extraordinary
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Table III. Determination of pefloxacin mesylate in formulations
Formulation
Nominal amount
(mg per tablet or mg per mL)
















B 400 98.7 ± 0.4 99.2 ± 0.6
t = 1.52
F = 2.12
C 400 100.2 ± 0.6 101.9±1.32
t = 2.77
F = 5.76
D 2 98.3 ± 0.6 99.2 ± 1.3
t = 1.76
F = 4.75
Tabulated t-value at 95% confidence level is 2.77; tabulated F-value at 95% confidence level is 6.39.
a Non-aqueous potentiometric titration.
sensitivity, which is comparable to that of the spectrofluorometric method. Further, owing
to the high sensitivity and selectivity of the method, it might be applied for measuring
PFM levels in biological fluids. Other advantages of the method include a wide linear
dynamic range, unassailable stability of the colour measured (colour stable for several
weeks) compared to many procedures reported earlier. This is demonstrated by the high
precision of the results. Further, once the drug-dye ion-pair is prepared, further extrac-
tions seldom use chloroform, unlike reported method (25).
CONCLUSIONS
Peflaxacin mesylate has been assayed in dosage forms using visible spectrophoto-
metry. The method can be used to monitor the content uniformity of tablets and injec-
tions, and purity of pefloxacin raw material.
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A (200 mg) 0.98 1.0 103.3 ± 1.1
0.98 2.0 97.0 ± 2.1
0.98 3.0 103.3 ± 1.3
A (400 mg) 1.0 1.0 102.0 ± 1.5
1.0 2.0 106.0 ± 1.1
1.0 3.0 97.3 ± 2.6
D 0.99 1.0 101.0 ± 2.7
0.99 2.0 97.0 ± 3.4
0.99 3.0 103.3 ± 4.1
a Mean ± SD, n = 3.
Table V. Selectivity data
Composition of synthetic mixture (mg) PFM
recovered











100 150 200 150 50 250 300 100 50 97.6 ± 0.8
a Mean ± SD, n = 5.
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S A @ E T A K
Spektrofotometrijsko odre|ivanje pefloksacin mesilata u ljekovitim oblicima
KANAKAPURA BASAVAIAH, HULLIKAL CHANDRASHEKAR PRAMEELA
i BANKAVADI CHIKKASWAMY SOMASHEKAR
Opisana je spektrofotometrijska metoda za odre|ivanje pefloksacin mesilata (PFM)
kao ~iste supstancije i u tabletama. Metoda se temelji na povratnoj ekstrakciji bromfenol
modrila pri pH 5,2 iz ionskog para boja-ljekovita tvar te mjerenju apsorbancije boje na
590 nm. Ispitivani su i optimirani reakcijski uvjeti. Sustav slijedi Beerov zakon u kon-
centracijskom rasponu 0,15–1,25 Mg mL–1 (R = 0,9986). Prema va`e}im ICH uputama
procijenjeni su indeksi osjetljivosti kao {to su molarni apsorpcijski koeficijent, granica
detekcije i granica odre|ivanja; tako|er su procijenjeni ispravnost i preciznost. Relativna
pogre{ka kretala se u rasponu –1,7 do 1,8%, a RSD vrijednosti izme|u 1,0 i 1,1%. Metoda
je uspje{no primjenjena za odre|ivanje PFM u tabletama s analiti~kim povratom od 97,5
do 101,9% uz RSD od 0,6 do 1,9%. Rezultati su statisti~ki uspore|eni s referentnom me-
todom pomo}u Studentovog t-testa i F-testa, ukazuju}i na usporedivu preciznost i is-
pravnost obiju metoda. Ispravnost procijenjena metodom standardne adicije kretala se u
rasponu od 97,0 do 106,0%, s precizno{}u (RSD) boljom od 3%.
Klju~ne rije~i: pefloksacin mesilat, odre|ivanje, spektrofotometrija, bromfenol modrilo, ljekoviti oblici
Department of Chemistry, University of Mysore, Manasagangotri, Mysore-570 006, India
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